hiv info source nyu medical center bellevue hospital center

The Prevention Project of the NYU Center for AIDS Research

Phone: 212-263-0362 Email: prevention@gcrc.med.nyu.edu


Under the direction of Dr. Michael Marmor, the Prevention Project is dedicated to behavioral and vaccine research for the prevention of HIV. Dr. Marmor has been working in preventive HIV research since the beginning of the HIV epidemic.

Current ongoing studies include:

  • F1RST CALL NYU at NYU School of Medicine is a comprehensive research program, funded by the cfar manNational Institutes of Health, for the identification and treatment of people with recent HIV infection. People who are found to have a recent infection are offered enrollment in the Primary HIV Infection Study , which offers free treatment options as well as research options for people who do not want treatment/medications.
  • The NYU Long-term Nonprogressors Study: A collaboration of research programs to learn about the immune systems of HIV-positive people.
  • The Prevention Cohort Study is a long-term study for HIV negative, at-risk individuals to receive ongoing HIV testing and risk reduction counseling. There are no medications used in this study.
  • The Merck 023 HIV Vaccine Study is a Phase II proof of concept study of an experimental vaccine that may one day prevent HIV infection or keep people who do become HIV-infected healthier. You cannot get HIV infection or AIDS by receiving this vaccine.
  • The Merck 027 HIV Vaccine Study is a Phase IIa dose refinement study. The purpose of the study is to compare different dosages of the Merck Adenovirus Serotype 5 HIV-1 gag/pol/nef vaccine. This vaccine is also being tested in the Merck 023 study.